Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABOLD: Cabozantinib and Nivolumab in older patients with renal-cell carcinoma
2024-516650-22-00Phase 4Authorised
- Sponsor
- Gustave Roussy
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabozantinib and nivolumab in renal cell carcinoma (RCC), sponsored by Gustave Roussy. Primary endpoint: Treatment patterns at 24 weeks. Planned start Feb 2025; status: authorised.
02
Drugs
cabozantinibnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-516650-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516650-22-00.